Alternating multiagent chemotherapy for advanced ovarian cancer

Area of Science:

• Oncology
• Medical Treatment

Background:

• Advanced epithelial ovarian cancer presents a significant treatment challenge.
• Effective chemotherapy regimens are crucial for improving patient outcomes.

Purpose of the Study:

• To assess the efficacy and toxicity of a novel chemotherapy regimen for advanced epithelial ovarian cancer.
• To evaluate clinical response rates and survival in patients receiving this regimen.

Main Methods:

• A chemotherapy regimen comprising hexamethylmelamine, cyclophosphamide, Adriamycin, and cis-diamminechloroplatinum was administered to 29 patients.
• Treatment involved a 28-day cycle with specific dosages and administration schedules.
• Toxicity and clinical response were closely monitored.

Main Results:

• The regimen demonstrated a 55% clinical response rate.
• Median survival was observed to be 14 months.
• Common toxicities included alopecia, nausea, and vomiting; severe toxicities were minimal.

Conclusions:

• The evaluated chemotherapy regimen is well-tolerated in patients with advanced epithelial ovarian cancer.
• This regimen achieves favorable response rates and survival durations.
• It offers a viable treatment option without compromising patient response.